Table 3.
Adjusted1 hazard rate ratios and 95% confidence intervals of incident cardiometabolic risk factors in women with hormone-receptor positive breast cancer by endocrine therapy use stratified by baseline body mass index groups
| Premenopausal Tamoxifen Users | p-value for interaction | Postmenopausal Tamoxifen Users | p-value for interaction | Aromatase Inhibitor Users | p-value for interaction | |
|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | ||||
| Normal Weight | ||||||
| Diabetes | Not Estimatable | 0.76 (0.26, 2.20) | 1.25 (0.69, 2.27) | |||
| Dyslipidemia | 1.07 (0.49, 2.35) | 0.82 (0.47, 1.45) | 1.71 (1.22, 2.38) | |||
| Hypertension | 0.76 (0.37, 1.56) | 1.57 (0.97, 2.56) | 1.45 (1.03, 2.04) | |||
| Overweight | ||||||
| Diabetes | 3.09 (0.66, 14.50) | NA | 0.52 (0.22, 1.24) | 0.83 | 1.19 (0.76, 1.85) | 0.98 |
| Dyslipidemia | 0.81 (0.40, 1.63) | 0.37 | 1.11 (0.61, 2.02) | 0.30 | 1.84 (1.27, 2.68) | 0.77 |
| Hypertension | 1.55 (0.75, 3.23) | 0.43 | 1.19 (0.68, 2.08) | 0.60 | 1.57 (1.13, 2.19) | 0.72 |
| Obese | ||||||
| Diabetes | 1.07 (0.48, 2.39) | NA | 2.05 (1.13, 3.74) | 0.08 | 1.49 (0.98, 2.26) | 0.54 |
| Dyslipidemia | 2.33 (0.96, 5.69) | 0.38 | 0.84 (0.48, 1.47) | 0.95 | 1.24 (0.89, 1.72) | 0.14 |
| Hypertension | 1.21 (0.64, 2.27) | 0.38 | 1.40 (0.83, 2.35) | 0.90 | 1.46 (1.05, 2.03) | 0.73 |
1
Adjusted for age, race/ethnicity, smoking status, AJCC stage, chemotherapy, radiation therapy, breast surgery, and prevalent (baseline) diabetes, dyslipidemia, and hypertension (when not the outcome of interest).